APOA1 and myeloid sarcoma: To explain the relationship between S100A12 or Apo-A1 and familial association, as well as display the mechanism action of S100A12/Apo-A1 as biomarkers in the high-risk group, future studies will require a larger sample size of high-risk and MS patient groups, other biomarkers, and genetic testing such as polymorphism analyses.